MyBioSource

antibody

Mouse Anti-Apoa5 (ab) Monoclonal Antibody

MBS130162

0.04 mg

150 USD

monoclonal

mouse

human

western blot, ELISA

MBS130162

Antibody

Mouse Anti-Apoa5 (ab) Monoclonal Antibody

Apoa5

apolipoprotein A-V; Apolipoprotein A-V; apolipoprotein A-V; apo-AV; apolipoprotein A5; OTTHUMP00000043271; OTTHUMP00000069351; regeneration-associated protein 3; apolipoprotein A-V; Apolipoprotein A5; Regeneration-associated protein 3

Apoa5

APOA5; APOA5; RAP3; APOAV; FLJ97995; MGC126836; MGC126838; RAP3

APOA5_HUMAN

Monoclonal

IgG1

Mouse

366

Human serum total protein (WB). human Apoa5 recombinant protein (ELISA)

Crude ascites

The antibody remains stable for one to two weeks if stored at 2 degree C to 8 degree C. For long-term storage. aliquot and store at -20 degree C or below. Use before is one year from the date of receipt.

ELISA, Western Blot

Western Blot: 1:2,000-1:5,000. ELISA: Determine optimal working dilutions by titration test.

Immunogen: Ni-NTA purified recombinant human APOA5 expressed in E. coli strain BL21 (DE3). Antigen Species: Human

Apolipoprotein A5 (ApoA5) is fast gaining attention as a key regulator of serum triglyceride concentrations. An ApoA5 mouse knock-out model produced an approximately four fold increase in serum triglycerides. whereas a knock-in model with human ApoA5 produced 50-70% lower concentrations of mouse serum triglycerides. In addition. peroxisome proliferator-activated receptor-_ agonists. which are used clinically to lower serum triglyceride concentrations. cause increased ApoA5 mRNA expression. Recently. it was demonstrated that ApoA5 is present in human serum detected by polyclonal antibodies against both the NH2 and COOH termini. although at much lower concentration than other apolipoproteins.

262231737

NP_001160070.1

NM_001166598.1

Q6Q788

41,213 Da

Chylomicron-mediated Lipid Transport Pathway 106157!!Fatty Acid, Triacylglycerol, And Ketone Body Metabolism Pathway 160977!!Lipid Digestion, Mobilization, And Transport Pathway 106111!!Lipoprotein Metabolism Pathway 106156!!Metabolism Of Lipids And Lipoproteins Pathway 160976!!PPAR Signaling Pathway 83042!!PPAR Signaling Pathway 450!!Regulation Of Lipid Metabolism By Peroxisome Proliferator-activated Receptor Alpha (PPARalpha) Pathway 119544!!Statin Pathway 198852

The protein encoded by this gene is an apolipoprotein that plays an important role in regulating the plasma triglyceride levels, a major risk factor for coronary artery disease. It is a component of high density lipoprotein and is highly similar to a rat protein that is upregulated in response to liver injury. Mutations in this gene have been associated with hypertriglyceridemia and hyperlipoproteinemia type 5. This gene is located proximal to the apolipoprotein gene cluster on chromosome 11q23. Alternatively spliced transcript variants encoding the same protein have been identified. [provided by RefSeq]

Function: Minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. May also be associated with chylomicrons. Important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and a inhibitor of the hepatic VLDL-TG production rate (without affecting the VLDL-apoB production rate). By similarity. Activates poorly lecithin:cholesterol acyltransferase (LCAT) and does not enhance efflux of cholesterol from macrophages. Ref.6 Ref.7 Ref.10. Subunit structure: Interacts with GPIHBP1. Ref.11. Subcellular location: Secreted Ref.9. Tissue specificity: Liver and plasma. Ref.1 Ref.6 Ref.10 Ref.12. Induction: Up-regulated by PPARA agonists, which are used clinically to lower serum TG (such as fibrates). Ref.8. Post-translational modification: Phosphorylation sites are present in the extracelllular medium. Polymorphism: Three common alleles are known: allele APOA5*1, APOA5*2 and APOA5*3. The APOA5*2 haplotype, which consists of 3 non-coding SNPs, is present in approximately 16% of Caucasians and is associated with increased plasma triglyceride concentrations. APOA5*3 haplotype is defined by the rare Ser-19-Trp substitution. Together, the APOA5*2 and APOA5*3 haplotypes are found in 25 to 50% of African Americans, Hispanics, and Caucasians. Involvement in disease: Defects in APOA5 are a cause of susceptibility to familial hypertriglyceridemia (FHTR)[. MIM:145750].mFamilial hypertriglyceridemia is a common inherited disorder in which the concentration of very low density lipoprotein (VLDL) is elevated in the plasma. This leads to increased risk of heart disease, obesity, and pancreatitis.Defects in APOA5 are a cause of hyperlipoproteinemia type 5 (HLPP5) [. MIM:144650]. HLPP5 is characterized by increased amounts of chylomicrons and very low density lipoprotein (VLDL) and decreased low density lipoprotein (LDL) and high density lipoprotein (HDL) in the plasma after a fast. Numerous conditions cause this phenotype, including insulin-dependent diabetes mellitus, contraceptive steroids, alcohol abuse, and glycogen storage disease type 1A (GSD1A) [. MIM:232200]. Ref.16. Miscellaneous: Induced in early phase of liver regeneration. Sequence similarities: Belongs to the apolipoprotein A1/A4/E family. Caution: It is uncertain whether Met-1 or Met-4 is the initiator. Sequence caution: The sequence AAF25661.1 differs from that shown. Reason: Erroneous initiation. The sequence AAF25662.1 differs from that shown. Reason: Erroneous initiation. The sequence AAQ89109.1 differs from that shown. Reason: Erroneous termination at position 275. Translated as Gln.

0.04 mg

150 USD